



PT IKAPHARMINDO PUTRAMAS Tbk
Pharmaceutical Laboratories

("Company")

ANNOUNCEMENT
SUMMARY OF MINUTES OF EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS

The Board of Directors of the Company hereby announces to the Shareholders of the Company that the Company has held an Extraordinary General Meeting of Shareholders ("EGMS").

In order to comply with the Financial Services Authority Regulation No.15/POJK.04/2020 concerning Planning and Implementation of the General Meeting of Shareholders of Public Listed Companies, the Company submitted Summary of Minutes of EGMS as follows:

Extraordinary General Meeting of Shareholders has been held on:

Day & Date : **Wednesday, September 25, 2024**
Time : 10.20 – 10.35 WIB
Venue : Klub Kelapa Gading
Jl. Bulevar Kelapa Gading Blok KGC
Summarecon Kelapa Gading
Jakarta, 14240, Indonesia

Agenda :

Approval of change to the purpose of Fund which obtained from Company's Public Offering

The attendance of Members of the Board of Directors and Board of Commissioners of the Company:

Members of the Board of Directors who attended the Meeting:

President Director : Mr. KARTONO;
Director : Mr. AYI SAEPUDIN;
Director : Mrs. Eliza Arlena Winata;

Members of the Board of Commissioners who attended the Meeting:

Independent Commissioner : Mr. SUSANTO LAM.

Meeting Chair:

-The meeting was chaired by Mr. SUSANTO LAM, as the Company's Independent Commissioner.

The Attendance of Shareholders:

-The Meeting has been attended by shareholders and shareholders' proxies representing 1.530.518.000 shares or represented 90,85% of 1.684.662.500 shares which are all shares with valid voting rights which issued by the Company after deducting the number of shares that have been repurchased by the Company.

Submission of Questions and/or Opinions:

-Shareholders and shareholders' proxies are given the opportunity to ask questions and/or gave opinions for agenda of the Meeting, but none of the shareholders and shareholders' proxies ask questions and/or gave opinions;

Decision Making Mechanism:

-Decision making of agenda is carried out based on deliberation for consensus, in the event that deliberation for consensus is not reached, decision making is carried out by voting.

Voting Results:

-Number of blank votes/abstain : 208.067.800 votes.
-Number of dissenting votes : - voice.
-Number of affirmative votes : 1.322.450.200 votes.
-So that the total votes are affirmative : 1.530.518.000 votes, or by 100%, or or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.067.800	-	1.322.450.200	1.530.518.000	100

Meeting Decision:

a. Approved the change in the plan for the use of fund which gained from Company's Public Offering, to be as follows:

- Use of the remaining fund which gained from the Company's Public Offering in the amount of Rp23,921,483,122.00 (twenty-three billion nine hundred twenty-one million four hundred eighty-three thousand one hundred twenty-two rupiah) which was originally:

- The remaining of capital expenditure fund for machinery in the amount of Rp6,448,153,740.00 (six billion four hundred forty-eight million one hundred fifty-three thousand seven hundred and forty rupiah); and
- The remaining of capital expenditure fund for building in the amount of Rp17,473,329,382.00 (seventeen billion four hundred seventy-three million three hundred twenty-nine thousand three hundred and eighty-two rupiah);

becomes:

- The remaining of capital expenditure fund for machinery in the amount of Rp6,448,153,740.00 (six billion four hundred forty eight million one hundred fifty three thousand seven hundred and forty rupiah) will still be used for goods, capital and machinery expenditure.
- The remaining fund in the amount of Rp17,473,329,382.00 (seventeen billion four hundred seventy three million three hundred twenty nine thousand three hundred and eighty two rupiah) will be used to increase the Company's capacity and strengthen its working capital structure.

b. Granted authority and power to the Company's Board of Directors, with the right to transfer this power to another person, to carry out all and any actions required in connection with the above decision.

Jakarta, September 25, 2024
Board of Directors
PT Ikapharmindo Putramas Tbk